Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone

Journal of Infectious Diseases

Volumn 175, Issue 4, 1997, Pages 901-904

  Oz, Helieh S ^a   Hughes, Walter T ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION SENSITIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RAT;

EID: 0030944969     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/513988     Document Type: Article

References (19)

1. Hughes WT, Smith B. Provocation of infection due to Pneumocystis carinii by cyclosporin A. J Infect Dis 1982; 145:767.
2. Hughes WT. Experimental animal models. In: Pneumocystis carinii pneumonitis. Boca Raton, FL: CRC Press, 1987:71-95.
3. Oz HS, Hughes WT. Effect of sex and dexamethasone dose on the experimental host for Pneumocystis carinii. Lab Anim Sci 1996;46: 109-10.
4. Gosio B. Ricerche bacteriologiche e chimiche sulle alterazioni del mais. Riv Igiene Sanita Pubblica 1896;7:825-68.
5. Florey HW, Gilliver K, Jennings MA, Sanders AG. Mycophenolic acid: an antibiotic from Penicillium brevicompactum diercks. Lancet 1946; 1:46-9.
6. Gilliver K. The inhibitory action of antibiotics on plant pathogenic bacteria and fungi. Ann Botany 1946; 10:271-82.
7. Abraham EP. The effect of mycophenolic acid on the growth of Staphylococcus aureus in heart broth. Biochem J 1945;39:398-408.
8. Quinn CM, Bugeja VC, Gallaghe JA, Whittaker PA. The effect of mycophenolic acid on the cell cycle of Candida albicans. Mycopathologia 1990;3:165-8.
9. Williams RH, Lively DH, DeLong DC, et al. Mycophenolic acid, antiviral and antitumor properties. J Antibacteria 1968; 21:463-4.
10. Ichimura H, Levy JA. Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus. Virology 1995;211:554-60.
11. Seki J, Shimada N, Takahashi K, et al. Inhibition of infectivity of human immunodeficiency virus by a novel nucleoside, oxetavocin, and related compounds. Antimicrob Agents Chemother 1989;33:773-5.
12. Affieri C, Allison AC, Kieff E. Effect of mycophenolic acid on Epstein-Barr virus infection of human B lymphocytes. Antimicrob Agents Chemother 1994;38:126-9.
13. Berman JD, Webster HK. In vitro effects of mycophenolic acid and allopurinol against Leishmania tropica in human macrophages. Antimicrob Agents Chemother 1982; 21:887-91.
14. Hupe DJ, Azzolina BA, Behrens ND. IMP dehydrogenase from the intracellular parasitic protozoan Eimeria tenella and its inhibition by mycophenolic acid. J Biol Chem 1986;261:8363-9.
15. O'Gara MS, Queener SF, Lee CH. Cloning and sequencing of the cDNA encoding Pneumocystis carinii inosine monophosphate dehydrogenase (IMPDH) [abstract F-13]. In: Proceedings of the annual meeting of the American Society for Microbiology (Las Vegas). Washington, DC: ASM, 1994:500.
16. Allison AC, Eugui EM. The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin Immunopathol 1993; 14:353-80.
17. Sollinger HW, Belzer FO, Deierhof MH, et al. RS-61443 (mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection. Ann Surg 1992;216:513-9.
18. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996;61:1029-37.
19. The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation 1996;61:722-29.